WO2007079953A3 - In vitro method to predict the tumor sensitivity to pharmacotherapy and endoradiotherapy - Google Patents

In vitro method to predict the tumor sensitivity to pharmacotherapy and endoradiotherapy Download PDF

Info

Publication number
WO2007079953A3
WO2007079953A3 PCT/EP2006/012424 EP2006012424W WO2007079953A3 WO 2007079953 A3 WO2007079953 A3 WO 2007079953A3 EP 2006012424 W EP2006012424 W EP 2006012424W WO 2007079953 A3 WO2007079953 A3 WO 2007079953A3
Authority
WO
WIPO (PCT)
Prior art keywords
iodine
bromine
malignant
amino acid
group
Prior art date
Application number
PCT/EP2006/012424
Other languages
French (fr)
Other versions
WO2007079953A2 (en
Inventor
Samuel Samnick
Andreas Kluge
Original Assignee
Samuel Samnick
Andreas Kluge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Samnick, Andreas Kluge filed Critical Samuel Samnick
Publication of WO2007079953A2 publication Critical patent/WO2007079953A2/en
Publication of WO2007079953A3 publication Critical patent/WO2007079953A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for the prediction of the sensitivity of malignant cells or malignant tissues to a cancer therapy which comprises the administration of a L-amino acid, conjugated to an alpha-, beta- or Auger-electron emitting isotope selected from the group consisting of bromine-76, bromine-77, bromine-82, iodine-123, iodine-124, iodine-125, iodine-131 and astatine-211 , wherein the L-amino acid is selected from the group consisting of phenylalanine, alanine, serine and cysteine. Moreover, the invention provides a pharmaceutical composition for an individual treatment of a malignant neoplasia and a kit for the prediction of the sensitivity of malignant cells or malignant tissues of an individual patient for such treatment. The invention also provides a use of one or more L-amino acid(s) selected from the group consisting of phenylalanine, alanine, serine and cysteine, conjugated to an alpha-, beta- or Auger-electron emitting isotope selected from the group consisting of bromine-76, bromine-77, bromine-82, iodine-123, iodine-124, iodine-125, iodine-131 and astatine-211 , for the preparation of a pharmaceutical composition for an individual patient for the treatment of malignant neoplasia, wherein for the selected one or more L-amino acid(s) a sensitivity of the malignant cells or malignant tissues from the individual patient is predicted by the method of the invention and a method for the individual treatment of a patient suffering from malignant neoplasia.
PCT/EP2006/012424 2005-12-21 2006-12-21 In vitro method to predict the tumor sensitivity to pharmacotherapy and endoradiotherapy WO2007079953A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05028068.4 2005-12-21
EP05028068 2005-12-21

Publications (2)

Publication Number Publication Date
WO2007079953A2 WO2007079953A2 (en) 2007-07-19
WO2007079953A3 true WO2007079953A3 (en) 2007-11-29

Family

ID=38256658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/012424 WO2007079953A2 (en) 2005-12-21 2006-12-21 In vitro method to predict the tumor sensitivity to pharmacotherapy and endoradiotherapy

Country Status (1)

Country Link
WO (1) WO2007079953A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145835A (en) * 2008-07-17 2013-06-12 协和发酵麒麟株式会社 Anti-system ASC amino acid transporter 2 (ASCT2) antibody

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2016103761A1 (en) * 2014-12-22 2017-11-02 ジェイファーマ株式会社 Cancer blood biomarkers
JP6707783B2 (en) * 2015-03-10 2020-06-10 国立大学法人群馬大学 Peptide compound and method for producing peptide compound
EP3663307A4 (en) * 2017-08-04 2021-03-24 Osaka University Production method for radiolabeled aryl compound
CN111836651A (en) * 2018-03-15 2020-10-27 国立大学法人大阪大学 Pharmaceutical composition comprising 211 At-labeled amino acid derivative and method for producing same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121787A2 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121787A2 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FUCHS B C ET AL: "Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHIA, PA, US, vol. 15, no. 4, August 2005 (2005-08-01), pages 254 - 266, XP004995897, ISSN: 1044-579X *
LIN JULES ET AL: "L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma", NEOPLASIA, DOYMA, BARCELONA,, ES, vol. 6, no. 1, January 2004 (2004-01-01), pages 74 - 84, XP002376775, ISSN: 0212-9787 *
ROMEIKE BERND F M ET AL: "ACTION AND EFFICACY OF P-131-IODO-L-PHENYLALANINE ON PRIMARY HUMAN GLIOMA CELL CULTURES AND RATS WITH C6-GLIOMAS", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 24, no. 6, November 2004 (2004-11-01), pages 3971 - 3976, XP009084572, ISSN: 0250-7005 *
SAMNICK SAMUEL ET AL: "P-123-IODO-L-PHENYLALANINE FOR DETECTION OF PANCREATIC CANCER:BASIC INVESTIGATIONS OF THE UPTAKE CHARACTERISTICS IN PRIMARY HUMAN PANCREATIC TUMOUR CELLS AND EVALUATION IN IN VIVO MODELS OF HUMAN PANCREATIC ADENOCARCINOMA", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER VERLAG, HEIDELBERG, DE, vol. 31, no. 4, 14 January 2004 (2004-01-14), pages 532 - 541, XP008078228, ISSN: 1619-7070 *
WECKESSER MATTHIAS ET AL: "Prognostic significance of amino acid transport imaging in patients with brain tumors.", NEUROSURGERY MAY 2002, vol. 50, no. 5, May 2002 (2002-05-01), pages 958 - 964 ; dis, XP009087734, ISSN: 0148-396X *
YANAGIDA O ET AL: "Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 1514, no. 2, 1 October 2001 (2001-10-01), pages 291 - 302, XP004319633, ISSN: 0005-2736 *
YOON JUNG HOON ET AL: "Expression and functional characterization of the system L amino acid transporter in KB human oral epidermoid carcinoma cells", CANCER LETTERS, NEW YORK, NY, US, vol. 205, no. 2, 18 March 2004 (2004-03-18), pages 215 - 226, XP002376776, ISSN: 0304-3835 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145835A (en) * 2008-07-17 2013-06-12 协和发酵麒麟株式会社 Anti-system ASC amino acid transporter 2 (ASCT2) antibody
CN103145835B (en) * 2008-07-17 2014-10-29 协和发酵麒麟株式会社 Anti-system asc amino acid transporter 2 (ASCT2) antibody

Also Published As

Publication number Publication date
WO2007079953A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
HK1102991A1 (en) Pharmaceutical formulation of decitabine
WO2007079953A3 (en) In vitro method to predict the tumor sensitivity to pharmacotherapy and endoradiotherapy
IS8485A (en) Use of substituted 2-aminotetralins in the prevention of Parkinson's disease
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
UA84420C2 (en) 1,2,4-oxadiazole benzoic acid compounds, pharmaceutical composition (variants) and their use for treating a disease ameliorated by modulation of premature translation termination or nonsense-mediated mrna decay
UA93043C2 (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
HN2002000317A (en) PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
WO2001055178A3 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
ES2328496T3 (en) 1,4,8-TRIAZA-ESPIRO (4,5) DECAN-2-ONA SUBSTITUTED COMPOUNDS.
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
PT1730147E (en) Substituted 1,4,8-triazaspiro[4,5]decan-2-on compounds for use in the treatment of obesity
MXPA05012645A (en) Novel pyridopyrazines and use thereof as kinase modulators.
HK1062923A1 (en) Igf-binding protein-derived peptide
RS20050864A (en) Novel pyridopyrazines and use thereof as kinase inhibitors
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
IL199340A0 (en) Treatment of pervasive developmental disorders
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
WO2006019685A3 (en) Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production
WO2005085466A3 (en) Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2007047553A3 (en) Methods and compositions for treatment of prostate intraepithelial neoplasia
NZ544481A (en) norgestrel 3e- and -3z-oxime isomers, as well as process for the synthesis of the mixture of isomers and the pure isomers
WO2007060012A3 (en) Use of l-phenylalanine conjugated to an emitting isotope for therapy of hormone dependent carcinoma

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06841111

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06841111

Country of ref document: EP

Kind code of ref document: A2